INTRODUCTION AND OBJECTIVES: Scrotal pain is a common complaint in urologic practice. To date, there is little data on the prevalence and treatment patterns of the disease. Moreover, little is known about the financial burden on the medical system. Thus, we sought to characterize scrotal pain and its impact among men in a large US insurance claims database.
INTRODUCTION AND OBJECTIVES: Scrotal pain is a common complaint in urologic practice. To date, there is little data on the prevalence and treatment patterns of the disease. Moreover, little is known about the financial burden on the medical system. Thus, we sought to characterize scrotal pain and its impact among men in a large US insurance claims database.
METHODS: We analyzed subjects from the Truven Health MarketScan claims database from 2007 to 2014. This US database provides information of insurance claims filed for the care of privatelyinsured individuals with employment-based insurance through a participating employer. Clinical encounters for scrotal pain were identified using ICD-9 codes. The total number of visits and patient demographics were enumerated. Codes for the pharmaceuticals prescribed for scrotal pain were also extracted and analyzed.
RESULTS: In 2007, 0.83% of all men older than 18 years of age (87,333 men) in our cohort were seen for scrotal pain increasing to 0.98% (154,840 men) in 2014. The mean number of visits per year for each patient who was evaluated at least once for their scrotal pain remained relatively constant, 1.38 visits per person in 2007 (62,943 total visits) and 1.40 in 2014 (117,419 total visits) with a mean patient age around 41 years. The mean cost of medications prescribed per year for each man with scrotal pain was $185.23 and the mean overall cost for these patients was $754.06 per year, which equates to roughly $116M in 2014. In 2007, the majority of pain medications prescribed for scrotal pain were opiates and NSAIDS at 14.5% and 11.0% of all men with scrotal pain, respectively. Opiate prescription increased to 43.4% and NSAIDS increased to 35.9% in 2014. Muscle relaxant and anticonvulsant prescription also increased substantially from 3.2% to 15.79% and 0.7% to 3.9%, respectively over the same time interval.
CONCLUSIONS: The incidence of scrotal pain has risen over the past 8 years affecting nearly 1% of all men and contributing to the high economic burden of this disease. The utilization of prescription medication is increasing with more men being prescribed opiates over the period of observation. Given the rising prevalence of scrotal pain and changing treatment patterns, greater epidemiologic understanding of this disease is necessary to ensure optimal management of these patients.
Source of Funding: None.
PD14-07 HEALTH SYSTEM STRUCTURE AND READMISSIONS AFTER UROLOGIC CANCER SURGERY
Anobel Odisho*, Ruth Etzioni, Seattle, WA; David Penson, Nashville, TN; John Gore, Seattle, WA INTRODUCTION AND OBJECTIVES: Readmissions have become a focus of quality improvement as policy makers emphasize the delivery of value-based care. Vertically integrated health systems have the greatest ability and incentive to minimize unplanned readmissions. We compare 30-day readmission rates for patients undergoing urologic oncology surgery between three types of health systems in California: an integrated health system (IHS), safety-net hospitals (SNH), and traditional hospital systems (non-SNH).
METHODS: We used California Office of Statewide Health Planning and Development data from 2007-2011, including all patients in California undergoing radical prostatectomy (RP) for prostate cancer, radical cystectomy (RC) for bladder cancer, and partial nephrectomy (PN) or radical nephrectomy (RN) for kidney cancer. We compared risk adjusted readmission rates using Medicare Hospital Readmissions Reduction Program models with the addition of patient socioeconomic status (SES). A separate model was used for each cohort. Comorbidity was assigned using the Elixhauser Index. Patient SES was derived from a Census based neighborhood score at the ZIP code level.
RESULTS: Overall, 19-21% of RP, RC, PN, and RN were performed at an IHS hospital; 5-9% at a SNH. There were 1,185 readmissions in RP, 999 in RC, 537 in PN, and 1,107 in RN. Unadjusted 30-day readmissions at IHS hospitals were 3.6% in compared to 3.1% in SNH and 3.3% in non-SNH, 26.7% for RC compared with 25.3% for non-SNH and 25.2% for SNH, 8.4% for PN compared with 9.6% for non-SNH and 10.7% for SNH, and 8.0% for RN compared with 8.3% for non-SNH and 9.5% for SNH (all non-significant). In multivariate models ( Table) , higher patient comorbidity was associated with increased readmission rates across all 4 cohorts. Additional factors associated with readmissions included female sex and open surgical approach in PN, and age, open approach, distance from hospital, and urban status in RN, and age in RP. Across all 4 surgical cohorts, hospital system type was not associated with readmissions.
CONCLUSIONS: Irrespective of health system structure, readmissions among urologic oncology patients are driven by patient characteristics, such as comorbidity, and not hospital type or health system structure. This has important implications for the delivery of value-based care as hospitals become more vertically integrated to improve outcomes. INTRODUCTION AND OBJECTIVES: Post-operative delirium is associated with poor outcomes and increased healthcare costs in the elderly. A population-based analysis of incidence, outcomes, and cost of delirium has not been characterized in major urologic cancer surgeries.
METHODS: Using the Premier Hospital Database, we retrospectively identified patients who had undergone radical prostatectomy (RP), radical nephrectomy (RN), partial nephrectomy (PN), and radical cystectomy (RC) from 2003 to 2013. Delirium was defined using International Classification of Disease, Ninth-Revision (ICD-9) codes, as well as post-operative use of antipsychotics, sitters, and restraints. We constructed regression models to assess for mortality, discharge disposition, length of stay (LOS), and direct hospital costs. Surveyweighted adjustment for hospital clustering was used to achieve estimates generalizable to the US population. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e279
